drugset
Drugs / GLA-LSQ
last change Nov 2024 re-read 2 minutes ago

GLA-LSQ

Other / unclassified

Investigated by
Access to Advanced Health Institute (AAHI) · Dynavax Technologies Corporation · Fred Hutchinson Cancer Center · HIV Vaccine Trials Network · International AIDS Vaccine Initiative · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

today NCT04177355 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04177355 Jan 2020 → Nov 2024 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02647489 Background May 2016 → Nov 2017 malaria University Hospital Tuebingen Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as GLA-LSQ ClinicalTrials.gov intervention name — accepted as the source's own label NCT04177355 ↗
1

NCT02647489 ↗
Action Activate “GLA-SE and GLA-LSQ, synthetic TLR-4 agonists with a strong immune stimulatory effect” NCT02647489 ↗
Modality Other / unclassified “GLA-SE and GLA-LSQ, synthetic TLR-4 agonists with a strong immune stimulatory effect” NCT02647489 ↗